Drug Details

General Information of the Drug (ID: DR8562)
Name
Pirarubicin
Synonyms
pirarubicin; 72496-41-4; Theprubicin; MFCD00869742; Therarubicin (TN); (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2S)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-6-methyl-5-(((S)-tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; THP-doxorubicin; C32H37NO12; NCGC00167982-01; Pirarubicin (JP17/INN); CHEMBL1398373; SCHEMBL15472856; CHEBI:32011; AOB5649; EX-A494; AMY10325; ZINC3913909; AKOS015895621; NCGC00167982-02; NCGC00167982-04; K234; D01885; 15207-EP2272827A1; 15207-EP2275420A1; 15207-EP2295055A2; 15207-EP2295416A2; 15207-EP2295426A1; 15207-EP2295427A1; 15207-EP2298748A2; 15207-EP2298764A1; 15207-EP2298765A1; 15207-EP2298768A1; 15207-EP2298778A1; 15207-EP2305642A2; 15207-EP2311453A1; 15207-EP2311808A1; 15207-EP2311829A1; 15207-EP2316832A1; 15207-EP2316833A1; 496P414; Pirarubicin, Antibiotic for Culture Media Use Only; Q-201589; (8S)-10-((2R,4S,5S,6S)-4-amino-6-methyl-5-((S)-tetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
    Click to Show/Hide
Molecular Type
Small molecule
Disease Breast cancer [ICD-11: 2C60] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C32H37NO12
PubChem CID
636397
Canonical SMILES
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OC6CCCCO6
InChI
1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21-,22-,31+,32-/m0/s1
InChIKey
KMSKQZKKOZQFFG-HSUXVGOQSA-N
CAS Number
CAS 72496-41-4
ChEBI ID
CHEBI:32011
TTD Drug ID
D0T8EH
DrugBank ID
DB11616
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Citral      Cymbogogon Citratus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression p105  Molecule Info 
Pathway MAP
                    In-vitro Model HCT 116 CVCL_0291 Colon carcinoma Homo sapiens
                    In-vivo Model For the colorectal peritoneal carcinomatosis (CRPC) experiments, mouse-derived colorectal cancer cells CT26 (5 * 106 cells in 0.5 mL of serum-free medium) were intraperitoneal inoculated into the flanks of Balb/C mice.
                    Experimental
                    Result(s)		 Combination treatment of citral potentiates the efficacy of hyperthermic intraperitoneal chemoperfusion with pirarubicin for colorectal cancer.
Target and Pathway
Target(s) Human Deoxyribonucleic acid (hDNA)  Molecule Info  [3]
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Reference 2 Combination Treatment of Citral Potentiates the Efficacy of Hyperthermic Intraperitoneal Chemoperfusion with Pirarubicin for Colorectal Cancer. Mol Pharm. 2017 Oct 2;14(10):3588-3597.
Reference 3 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
 Download Picture         KEGG Link